

# **Test Definition: FINA**

NAbFeron (IFNB-1) Neutralizing Antibody Test

# **Overview**

# **Useful For**

Detection of antibodies to interferon-B-1

#### **Method Name**

Viral cytopathic effect assay

#### **NY State Available**

Yes

# **Specimen**

# **Specimen Type**

Serum

# Specimen Required Specimen Type: Serum

Container/Tube: Red or SST Specimen Volume: 2 mL

**Collection Instructions**: Draw blood in a plain red-top tube(s), serum gel tube is acceptable. Spin down and send 2 mL of serum refrigerate in a plastic vial.

**Note**: Sample needs to be collected either before treatment with interferon or more than 24 hours following the most recent dose. Patient should not be on steroid therapy for at least two weeks prior to testing.

# **Specimen Minimum Volume**

0.5 mL

# **Reject Due To**

| Hemolysis | NA |
|-----------|----|
| Lipemia   | NA |
| Icterus   | NA |
| Other     | NA |

# **Specimen Stability Information**

| Specimen Type | Temperature              | Time    | Special Container |
|---------------|--------------------------|---------|-------------------|
| Serum         | Refrigerated (preferred) | 28 days |                   |



# **Test Definition: FINA**

NAbFeron (IFNB-1) Neutralizing Antibody Test

| ı | _       | _        |  |
|---|---------|----------|--|
|   | Ambient | 72 hours |  |
|   | Frozen  | 180 days |  |

# **Clinical & Interpretive**

#### Reference Values

Final report has been sent to the referring laboratory.

#### **Cautions**

The present of neutralizing antibodies to interferon beta, especially in persistently high titers, may be associated with reduction in the clinical effectiveness of interferon beta therapy (1). Although the measurement of Nabs can add to the clinical and imaging information used to assess the efficacy of interferon beta therapy, these results should be interpreted in the context of clinical presentation and medical history (2, 3).

Although rare, false positive or false negative results may occur. All results should be interpreted in the context of clinical findings, relevant history, and other laboratory data.

#### Clinical Reference

- 1. Goodin, DS, et al. (2007) Neurology 68:977-984 (PMID: 17389300)
- 2. Polman, CH, et al.(2010) Lancet Neurol 9:740-50 (PMID: 20610349)
- 3. Creeke, Pl, et al. (2013) Ther Adv Neurol Disord 6:3-17 (PMID: 23277789)

#### **Performance**

# **PDF Report**

Referral

# Day(s) Performed

Monday through Friday

# **Report Available**

14 to 25 days

# **Performing Laboratory Location**

Athena Diagnostics

#### **Fees & Codes**

#### Fees

- Authorized users can sign in to <u>Test Prices</u> for detailed fee information.
- Clients without access to Test Prices can contact <u>Customer Service</u> 24 hours a day, seven days a week.



# **Test Definition: FINA**

# NAbFeron (IFNB-1) Neutralizing Antibody Test

• Prospective clients should contact their account representative. For assistance, contact <u>Customer Service</u>.

# **Test Classification**

This test was developed and its analytical performance characteristics have been determined by Athena Diagnostics. It has not been cleared or approved by U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes. .

# **CPT Code Information**

86382

# **LOINC®** Information

| Test ID | Test Order Name           | Order LOINC® Value |
|---------|---------------------------|--------------------|
| FINA    | NAbFeron (IFN-B) Antibody | Not Provided       |
|         |                           |                    |

| Result ID | Test Result Name          | Result LOINC® Value |
|-----------|---------------------------|---------------------|
| Z0083     | NAbFeron (IFN-B) Antibody | Not Provided        |